Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

• Status: Not yet recruiting
• Trial end date: 2024-10-01

Summary

This is a phase II, single-arm, multi-center, prospective clinical study of camrelizumab in combination with liposomal doxorubicin and losartan in patients with advanced or locally advanced triple-negative breast cancer who had received no more than 1 prior line of chemotherapy. Our aim was to explore the efficacy and safety of it.

• Phase: Phase 2

Details

• Lead Sponsor: Wuhan Union Hospital, China
• Collaborators: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Doxorubicin; Liposomal doxorubicin; Losartan